(11)        Subsequent Events

On July 16, 2026, the Company's shareholders approved the Radnostix 2026 Incentive Plan (the “2026 Plan”) as part of the Company's Annual Meeting. The 2026 Plan makes available for grant 12,000,000 shares. The 2026 Plan permits the grant of options, stock appreciation rights, restricted stock, restricted stock units, performance awards and other stock- or cash-based awards. The specific terms and conditions of awards, including vesting, performance criteria and settlement, will be determined by the Compensation Committee. The 2026 Plan terminates on July 16, 2036.

In response to the FDA Form 483 issued in April 2025, the Company completed all planned corrective and preventive actions. A request for inspection closeout was submitted to the FDA on June 19, 2026. In addition, the Company continues to execute initiatives designed to strengthen its Quality Management System, with all actions scheduled for completion in July 2026 completed on time.